MAPT and Alzheimer disease: However, measurement of AD biomarkers, e.g. tau protein and Aβ(1–42), in blood samples may face analytical challenges due to their low abundance relative to the very high levels of plasma proteins, resulting in matrix interference, as well as possible biological confounders such as expression of these proteins in peripheral tissue with release into plasma40.